Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC-MedSci.cn

Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC

Janne, P; Rajagopalan, R; Pudussery, G; Shrestha, P; Chen, S; Hodge, R; Qiu, Y; Yu, C

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (3): S237

科室
- - 订阅+
  - 更多科室
工具
服务